CoChat

Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients

Open access
Frémond, Marie-Louise, Hadchouel, Alice, Berteloot, Laureline, Melki, Isabelle, Bresson, Violaine, Barnabei, Laura, Jeremiah, Nadia, Belot, Alexandre, Bondet, Vincent, Brocq, Olivier, Chan, Damien, Dagher, Rawane, Dubus, Jean-Christophe, Duffy, Darragh, Feuillet-Soummer, Séverine, Fusaro, Mathieu, Gattorno, Marco, Insalaco, Antonella, Jeziorski, Eric, Kitabayashi, Naoki, Lopez-Corbeto, Mireia, Mazingue, Françoise, Morren, Marie-Anne, Rice, Gillian I., Rivière, Jacques G., Seabra, Luis, Sirvente, Jérôme, Soler-Palacin, Pere, Stremler-Le Bel, Nathalie, Thouvenin, Guillaume, Thumerelle, Caroline, Van Aerde, Eline, Volpi, Stefano, Willcocks, Sophie, Wouters, Carine, Breton, Sylvain, Molina, Thierry, Bader-Meunier, Brigitte, Moshous, Despina, Fischer, Alain, Blanche, Stéphane, Rieux-Laucat, Frédéric, Crow, Yanick J., Neven, Bénédicte · 2021 · The Journal of Allergy and Clinical Immunology: In Practice
Cited by 218

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Gain-of-function mutations in STING1 underlie a type I interferonopathy termed SAVI (STING-associated vasculopathy with onset in infancy). This severe disease is variably characterized by early-onset systemic inflammation, skin vasculopathy, and interstitial lung disease (ILD). OBJECTIVE: To describe a cohort of patients with SAVI. METHODS: Assessment of clinical, radiological and immunological data from 21 patients (17 families) was carried out. RESULTS: Patients carried heterozygous substitutions in STING1 previously described in SAVI, mainly the p.V155M. Most were symptomatic from infancy, but late onset in adulthood occurred in 1 patient. Systemic inflammation, skin vasculopathy, and ILD were observed in 19, 18, and 21 patients, respectively. Extensive tissue loss occurred in 4 patients. Severity of ILD was highly variable with insidious progression up to end-stage respiratory failure reached at teenage in 6 patients. Lung imaging revealed early fibrotic lesions. Failure to thrive was almost constant, with severe growth failure seen in 4 patients. Seven patients presented polyarthritis, and the phenotype in 1 infant mimicked a combined immunodeficiency. Extended features reminiscent of other interferonopathies were also found, including intracranial calcification, glaucoma and glomerular nephropathy. Increased expression of interferon-stimulated genes and interferon α protein was constant. Autoantibodies were frequently found, in particular rheumatoid factor. Most patients presented with a T-cell defect, with low counts of memory CD8+ cells and impaired T-cell proliferation in response to antigens. Long-term follow-up described in 8 children confirmed the clinical benefit of ruxolitinib in SAVI where the treatment was started early in the disease course, underlying the need for early diagnosis. Tolerance was reasonably good. CONCLUSION: The largest worldwide cohort of SAVI patients yet described, illustrates the core features of the disease and extends the clinical and immunological phenotype to include overlap with other monogenic interferonopathies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaip.2020.11.007

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 218

Metadata

Authors
Frémond, M.-L., Hadchouel, A., Berteloot, L., Melki, I., Bresson, V., Barnabei, L., Jeremiah, N., Belot, A., Bondet, V., Brocq, O., Chan, D., Dagher, R., Dubus, J.-C., Duffy, D., Feuillet-Soummer, S., Fusaro, M., Gattorno, M., Insalaco, A., Jeziorski, E., Kitabayashi, N., Lopez-Corbeto, M., Mazingue, F., Morren, M.-A., Rice, G. I., Rivière, J. G., Seabra, L., Sirvente, J., Soler-Palacin, P., Stremler-Le Bel, N., Thouvenin, G., Thumerelle, C., Van Aerde, E., Volpi, S., Willcocks, S., Wouters, C., Breton, S., Molina, T., Bader-Meunier, B., Moshous, D., Fischer, A., Blanche, S., Rieux-Laucat, F., Crow, Y. J., & Neven, B.
Venue
The Journal of Allergy and Clinical Immunology: In Practice
Publisher
Elsevier BV
Published
2021-02
Volume
9
Issue
2
Pages
803-818.e11
ISSN
2213-2198 (ISSN-L)
OpenAlex
W3099463467
Cited by
218
References
6
FWCI
6.94
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.